Sensex slumps 1.1% ahead of U.S. Fed meet
The Hindu
Indian equity markets slumped by more than 1% following nervousness ahead of the U.S. Fed policy meeting on Thursday.
An accommodative policy could stabilise global markets, analysts said, adding that the rise in COVID-19 cases fuelled selling pressure. Extending losses to the fourth session in a row, the S&P BSE Sensex fell 1.12% or 562 points to 49,801.62 on broad-based selling. PSU and banking stocks were most impacted. The NSE Nifty 50 too dipped 1.27% to 14,721.30.
L&T confirms 95% of its West Asia project sites are safe, while addressing logistics challenges amid ongoing regional conflicts.
Mines Ministry to auction 19 critical mineral blocks on March 23, expanding strategic resources for clean energy and technology sectors.
Mines Ministry to auction 19 critical mineral blocks on March 23, expanding strategic resources for clean energy and technology sectors.
Five top firms lose ₹1 lakh crore in market value, with HDFC Bank experiencing the largest decline of ₹56,124.48 crore.
HDFC Bank terminates three senior officials over client onboarding issues at its DIFC branch amid ethical concerns following chairman's resignation.
Air India CEO warns of potential flight cuts and reduced travel demand due to rising fuel costs amid ongoing Gulf conflict.
Options are widely used by retail traders to speculate on the value of the stock for immediate gains and such behaviour in large scale can distort the market
India achieves 1 billion tonne coal production for the second consecutive year, ensuring stable energy supply and economic growth.
Generic drugmakers in India launch affordable Semaglutide versions, targeting a $1 billion diabetes and weight loss market.
Indian and Asian refiners eye Iranian oil purchases as U.S. waives sanctions amid energy crisis linked to the Iran-Israel war.
Iran war impacts pesticide prices, warning of a 20-25% rise and increased risk of counterfeit products during the kharif season.
India's forex reserves fell by $7 billion to $709.76 billion, according to RBI data for the week ending March 13.
Natco Pharma will launch its Semaglutide injection (multi dose vials) in the domestic market on Saturday.